Dragon and Tiger List | ALK (002940) hit the limit down, with the top 5 sell orders totaling 123 million yuan. Reason for being on the list: The daily decline deviation reached 7% for the top 5 securities同壁财经·May 22 at 05:36 AM002940+3.67%
Innovative drug concept repeatedly active, ALK straight to the daily limit, Rundu Pharma previously sealed the board, InventisBio, Junshi Biosciences, HWPC, and Biokin Pharmaceutical rose more than 6%Wallstreetcn·Mar 31 at 09:07 PM159892+0.42%516820+0.29%
A-share innovative drug concept stocks are active again, Sunshine Guojian Pharmaceutical rose over 10% to a new high, Yatai Pharm had two consecutive limit-ups, WECOME rose over 10%, and Baicheng Pharmaceutical, ALK, and Fushine followed suitZhitong·Nov 2, 2025 at 07:48 PM300878+12.66%300497+2.39%
ALK: Starting in 2026, research and development investment will focus more on innovative drug projectsZhitong·Oct 29, 2025 at 10:15 PM002940+3.67%
ALK: Subsidiary obtains approval number for "Amoxicillin Clavulanate Potassium Tablets" veterinary drug productZhitong·Oct 28, 2025 at 06:45 AM002940+3.67%
ALK released its performance for the first three quarters, with a net profit attributable to the parent company of 77.6899 million yuan, a year-on-year increase of 55.59%Zhitong·Oct 24, 2025 at 11:53 AM002940+3.67%
The innovative drug concept strengthened at the beginning of the trading session, with MEDISAN and ALK both hitting the daily limitZhitong·Oct 21, 2025 at 08:41 PM002900-1.56%002940+3.67%
ALK: The ALK-N001 project is still in Phase I clinical trialsZhitong·Oct 19, 2025 at 03:18 AM002940+3.67%
ALK: Obtained the drug registration certificate for Levofloxacin TabletsZhitong·Oct 19, 2025 at 02:34 AM002940+3.67%
The Shanghai Composite Index rose 1.22%, returning to 3,900 points, with nearly 4,400 stocks in the entire market risingWallstreetcn·Oct 15, 2025 at 02:06 AM002050+5.22%002940+3.67%
The three major A-share indices collectively rose at the midday break, with the innovative drug concept experiencing a surge36Kr·Oct 14, 2025 at 10:36 PM002244-3.27%300436+2.95%
Zhejiang ALK received the "Drug Registration Certificate" for Amlodipine Besylate Tablets from the U.SZhitong·Oct 13, 2025 at 03:40 AM002940+3.67%
2025 Fund Mid-Year Report Insight: Pharmaceuticals, Banks, and Electronics Become Key Areas for Increased Holdings, Staidson BioPharm Fund's Shareholding Ratio Ranks FirstZhitong·Sep 2, 2025 at 01:36 AM002940+3.67%300204+4.82%
Innovative drug concept stocks fell in the afternoon, with Staidson BioPharm down over 10%Zhitong·Sep 2, 2025 at 12:17 AM002940+3.67%300158+1.23%
ALK released its performance for the first half of the year, with a net profit attributable to the parent company of 65.9251 million yuan, a year-on-year decrease of 3.19%Zhitong·Aug 27, 2025 at 11:02 AM002940+3.67%
